Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Lucid Diagnostics Inc. (NASDAQ:LUCD) has been assigned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $4.1875.

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, July 20th. Maxim Group decreased their price target on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Wall Street Zen lowered shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. BTIG Research reaffirmed a “buy” rating and set a $2.50 price objective on shares of Lucid Diagnostics in a research note on Friday, May 15th. Finally, Ascendiant Capital Markets increased their price objective on shares of Lucid Diagnostics from $9.00 to $9.25 and gave the company a “buy” rating in a report on Monday, June 8th.

Lucid Diagnostics Price Performance

Shares of NASDAQ:LUCD opened at $0.91 on Monday. Lucid Diagnostics has a 1 year low of $0.90 and a 1 year high of $1.63. The firm has a market capitalization of $184.31 million, a PE ratio of -1.93 and a beta of 1.07. The business’s 50 day moving average price is $1.02 and its 200-day moving average price is $1.15.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.26 million during the quarter, compared to analysts’ expectations of $1.38 million. As a group, analysts expect that Lucid Diagnostics will post -0.23 earnings per share for the current year.

Insider Buying and Selling at Lucid Diagnostics

In related news, Director Dennis Matheis bought 245,000 shares of the stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $245,000.00. Following the acquisition, the director directly owned 1,033,443 shares in the company, valued at approximately $1,033,443. This trade represents a 31.07% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lucid Diagnostics

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its stake in Lucid Diagnostics by 41.5% during the third quarter. Bank of America Corp DE now owns 40,663 shares of the company’s stock worth $41,000 after buying an additional 11,917 shares during the last quarter. Pine Valley Investments Ltd Liability Co grew its holdings in Lucid Diagnostics by 73.2% in the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 34,283 shares of the company’s stock valued at $39,000 after buying an additional 14,487 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Lucid Diagnostics by 35.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock worth $129,000 after acquiring an additional 22,727 shares during the last quarter. Centiva Capital LP acquired a new stake in shares of Lucid Diagnostics in the 3rd quarter worth $25,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Lucid Diagnostics in the 1st quarter worth $39,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.